Please assess the completion status of the following clinical trial:

Trial Title: A Trial of MBC-11 in Patients With CIBD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed malignant tumor (breast cancer, prostate cancer etc)~* Bone metastases, documented by radiographs, bone scan~* No available standard chemotherapy or no indication for chemotherapy at the time of screening~* Eastern Cooperative Oncology Group \[ECOG\] status 0-2~* Adequate bone marrow function (hemoglobin ≥ 9 g/dL with or without transfusion requirement, absolute neutrophil count ≥ 1500/mm3, and platelets ≥ 75,000/mm3)~* Adequate liver function (bilirubin ≤ 2 x Upper Limit of Normal \[ULN\], Alanine aminotransferase \[ALT\] ≤ 2.5 x ULN).~* Adequate renal function (creatinine ≤ 1.5 x ULN) and creatinine clearance ≥ 50 mL/min \[measured or calculated by nomogram\]).~Exclusion Criteria:~* Systemic chemotherapy and/or investigational therapy within the previous 4 weeks~* Fracture ≤ 6 month prior the inclusion in the study~* Brain metastasis~* Serum calcium levels \< 8.5 mg/dL (\< 2.2 mmol/L)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dose escalation of MBC-11 (Type: EXPERIMENTAL): MBC-11 was administered in 5 consecutively recruited cohort in dose 0.5 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg,10 mg/kg accordingly. The dose escalation is aimed at determining the maximum tolerated dose (MTD)

Based on this trial design, predict the completion outcome and termination type (if applicable).